20 (AIDX) Non-Current Deffered Revenue (2024 - 2026)

20 posted quarterly Non-Current Deffered Revenue of $37055.0 for Q1 2026, down 11.39% on a QoQ basis from $41816.0 in Q4 2025.

20 (AIDX) has 3 years of Non-Current Deffered Revenue data on file, last reported at $37055.0 in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $37055.0; the trailing twelve-month figure through Mar 2026 stood at $37055.0 (changed N/A YoY), and the FY2025 full-year result was $41816.0, down 16.37% from the prior year.
  • Non-Current Deffered Revenue for Q1 2026 stood at $37055.0, down from $41816.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $50000.0 in Q4 2024 and bottomed at $37055.0 in Q1 2026.
  • The 3-year median for Non-Current Deffered Revenue is $41816.0 (2025), against an average of $42957.0.
  • Peak annual rise in Non-Current Deffered Revenue reached 16.37% in 2025, while the deepest fall reached 16.37% in 2025.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $50000.0 in 2024, then fell by 16.37% to $41816.0 in 2025, then retreated by 11.39% to $37055.0 in 2026.
  • The last three Non-Current Deffered Revenue figures came in at $37055.0 (Q1 2026), $41816.0 (Q4 2025), and $50000.0 (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 512.79 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 20 - - 62,884.00 37,055.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 37,055.00
Dec 31, 2025 41,816.00
Dec 31, 2024 50,000.00